



HAL
open science

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice

Javed Butler, Faiez Zannad, Gerasimos Filippatos, Stefan D Anker, Milton Packer

► To cite this version:

Javed Butler, Faiez Zannad, Gerasimos Filippatos, Stefan D Anker, Milton Packer. Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. *European Heart Journal*, 2020, 41 (36), pp.3398-3401. 10.1093/eurheartj/ehaa731 . hal-03010031

HAL Id: hal-03010031

<https://hal.univ-lorraine.fr/hal-03010031>

Submitted on 17 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice

Javed Butler¹, Faiez Zannad², Gerasimos Filippatos ³, Stefan D. Anker⁴, and Milton Packer ^{5,6*}

¹Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA; ²Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France; ³National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece; ⁴Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany; ⁵Baylor Heart and Vascular Institute, Baylor University Medical Center, 621 N. Hall Street, Dallas, TX 75226, USA; and ⁶The Imperial College, London, UK

Received 9 August 2020; revised 20 August 2020; editorial decision 21 August 2020; accepted 24 August 2020; online publish-ahead-of-print 15 September 2020

Sodium–glucose co-transporter-2 (SGLT2) inhibitors exert favourable effects on the heart and kidney that cannot be explained by their glucose-lowering effect. In five trials with four different agents, SGLT2 inhibitors reduce the risk of heart failure hospitalizations and mitigate the progression of chronic kidney disease in patients with type 2 diabetes.^{1–3} Other antihyperglycaemic agents do not exert these benefits within 1–2 years of the onset of treatment, even though many have greater effects to lower blood glucose.⁴

Benefits on heart failure events in trials of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes, with or without heart failure

When the findings in trials in diabetes are combined, treatment with SGLT2 inhibitors is accompanied by $\approx 30\%$ reduction in the risk of heart failure hospitalization and a $\approx 40\text{--}50\%$ reduction in the risk of serious adverse renal events, including the development of end-stage kidney disease.¹ The magnitude of these benefits is consistent across the various trials, and the effects are statistically robust and clinically important. However, in contrast to these striking effects on non-fatal events, these drugs have inconsistent effects on mortality. Depending

on the trial, estimates of a treatment effect on survival have varied from virtually no reduction to as high as $\approx 40\%$ decrease in risk.^{5,6} Accordingly, when the effects of SGLT2 inhibitors on cardiovascular death in individual trials were combined in a meta-analysis, the magnitude of the mortality benefit was modest (a 15% reduction in risk) and characterized by significant heterogeneity.¹

The consistency of the effect on non-fatal heart failure events and the inconsistency of the effect on cardiovascular death is well-illustrated in two trials with dapagliflozin and empagliflozin in type 2 diabetes (DECLARE-TIMI58 and EMPA-REG OUTCOMES, respectively), Table 1. Both trials demonstrated a similar and robust reduction in the risk of heart failure hospitalizations as well as a decrease in the risk of clinically important progression of renal disease.^{5,6} However, when all randomized patients are considered, SGLT2 inhibition reduced the risk of cardiovascular death by 38% in the trial with empagliflozin but by only 2% in the trial with dapagliflozin. When the analysis is confined to comparable groups of patients (i.e. those with a prior myocardial infarction), the risk reductions for cardiovascular death were 41% in the trial with empagliflozin and 8% in the trial with dapagliflozin.^{7,8} These two estimates represent opposite extremes of the pooled estimate of a 15% reduction in the risk of death reported in a meta-analysis.¹

Most of the patients in the trials of SGLT2 inhibitors in type 2 diabetes did not have heart failure at the time of enrolment, and the phenotype of heart failure was not well-characterized. Since the

The opinions expressed in this article are not necessarily those of the Editors of the *European Heart Journal* or of the European Society of Cardiology.

* Corresponding author. Tel: 214-820-7500, Email: milton.packer@baylorhealth.edu

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

investigators did not routinely perform cardiac imaging, it was unclear if the effect of these drugs to reduce heart failure events applied to patients with a reduced or preserved ejection fraction. However, in the DECLARE-TIMI58 trial, the benefit on cardiovascular death or hospitalization for heart failure was greater in those with reduced ejection fraction than with a preserved ejection fraction at baseline (hazard ratio 0.62, 95%CI 0.45–0.86 and 0.88, 95%CI 0.76–1.02, respectively, interaction $P = 0.046$).⁹ The benefit was particularly striking in those with an ejection fraction $\leq 30\%$.

In addition to a lack of information regarding the phenotype of heart failure, the trials of SGLT2 inhibitors in type 2 diabetes provided little insight about the concomitant use of drugs that are known to prolong survival in patients with heart failure. Therefore, it was not known whether SGLT2 inhibitors would reduce risk of heart failure hospitalizations if patients had received optimal treatment for heart failure. Although many patients in the trials of type 2 diabetes were receiving inhibitors of the renin-angiotensin system and beta-adrenergic receptor blockers, most were not receiving mineralocorticoid receptor antagonists or neprilysin inhibitors. In one trial, concomitant treatment with spironolactone and eplerenone appeared to attenuate the ability of SGLT2 inhibitors to reduce heart failure events.¹⁰ Furthermore, because the cardiovascular outcome trials in type 2 diabetes were carried out before the availability of sacubitril/valsartan, it was not clear how inhibitors of SGLT2 and neprilysin might interact. Therefore, it was important to carry out large-scale definitive trials of SGLT2 inhibitors in patients with well-characterized heart failure who were taking all appropriate treatments for heart failure, including the use of cardiac devices.¹¹

Benefits on heart failure events in trials of sodium–glucose co-transporter-2 inhibitors in patients with heart failure and a reduced ejection fraction, with or without type 2 diabetes

Two large-scale trials of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction have now been completed, Table 1. The DAPA-HF and EMPEROR-Reduced trials both enrolled patients with classes II, III, and IV heart failure due to an ischaemic or non-ischaemic cardiomyopathy who were routinely treated with inhibitors of the renin-angiotensin system and beta-blockers, and (in the majority of patients) with mineralocorticoid receptor antagonists.^{12,13} Half of the patients in each trial did not have type 2 diabetes. Compared with the DAPA-HF trial with dapagliflozin, the EMPEROR-Reduced trial with empagliflozin was enriched for patients with more severe disease, i.e. patients in EMPEROR-Reduced had lower ejection fractions (27% vs. 31%), higher levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) (≈ 1900 vs. ≈ 1450 pg/mL) and lower glomerular filtration rates (62 vs. 66 mL/min/m²), and were more likely to be treated with sacubitril/valsartan ($\approx 20\%$ vs. $\approx 10\%$). Accordingly, the rate per 100 patient-years of follow-up for the composite of cardiovascular death and

heart failure hospitalization was $\approx 15\%$ in DAPA-HF, but $\approx 21\%$ in the EMPEROR-Reduced trial.

Although the two trials enrolled overlapping and complementary patient populations, the two trials reported highly concordant results. The combined risk of cardiovascular death or hospitalization for heart failure was reduced by 25% in each of the two trials, an effect that was highly statistically significant and consistent across pre-defined subgroups. In both trials, this benefit was largely driven by a reduction in the risk of a first hospitalization for heart failure by $\approx 30\%$. These benefits were seen and were of similar magnitude in patients and without diabetes and whether patients were receiving mineralocorticoid receptor antagonists or neprilysin inhibitors. Additionally, both trials reported a meaningful improvement in quality-of-life and excellent tolerability. These striking benefits were seen even though the median duration of follow-up in the two trials (16–18 months) was meaningfully shorter than in the trials with SGLT2 inhibitors in patients with type 2 diabetes (3–4 years).

Both trials reported a lower risk of a composite of clinically important renal events (chronic dialysis, renal transplantation, or the onset of a sustained and profound decrease in renal function) with a 29% risk reduction in DAPA-HF and a 50% risk reduction in EMPEROR-Reduced. The benefit on renal events reached nominal statistical significance in the trial with empagliflozin, but not in the trial with dapagliflozin, Table 1. In contrast, the risk of cardiovascular death was reduced by 18% in the DAPA-HF and by 8% in the EMPEROR-Reduced trial. The benefit was nominally significant in the trial with dapagliflozin but not in the trial with empagliflozin. This variability highlights the difficulties in reaching conclusions when an analysis focuses on non-primary endpoints in an individual trial, especially when the duration of double-blind treatment is short and when the trial was not specifically designed or powered to evaluate a specific effect. If the totality of evidence is ignored, the mortality effect might appear to be greater with dapagliflozin than with empagliflozin in two trials of patients with heart failure and a reduced ejection (with or without type 2 diabetes), whereas the mortality effect might appear to be greater with empagliflozin than with dapagliflozin in two trials of patients with type 2 diabetes (with or without heart failure). When the totality of evidence is considered, the degree of heterogeneity was highly significant in the trials of patients with type 2 diabetes,¹ but no heterogeneity was observed in trials of patients with heart failure and a reduced ejection fraction.¹⁴ This pattern of inconsistency should be expected when the magnitude of the effect size is modest. The risk reduction for all-cause mortality was 15% in the meta-analysis of the trials with type 2 diabetes and in 13% in the meta-analysis of the trials of heart failure with a reduced ejection fraction.^{1,14}

Conclusions

The totality of evidence from two large-scale randomized placebo-controlled trials (considered together with the findings in trials in type 2 diabetes) demonstrates a strikingly consistent effect of SGLT2 inhibition with dapagliflozin and empagliflozin to favourably affect the clinical course of heart failure, including a reduction in major adverse cardiovascular and renal outcomes. These benefits are attained regardless of the presence or absence of diabetes or the use of

Table 1 Effects of dapagliflozin and empagliflozin on heart failure and renal outcomes in trials of patients with type 2 diabetes and in trials of patients with heart failure with a reduced ejection fraction

Trials in type 2 diabetes (with or without heart failure)		
	DECLARE-TIMI58 (dapagliflozin)	EMPA-REG OUTCOME (empagliflozin)
Cardiovascular death or hospitalization for heart failure	0.83 (0.73–0.95) [913 events]	0.66 (0.55–0.79) [463 events]
First hospitalization for heart failure	0.73 (0.61–0.88) [498 events]	0.65 (0.50–0.85) [221 events]
Renal composite endpoint	0.53 (0.43–0.66) [365 events]	0.54 (0.40–0.75) [152 events]
Cardiovascular death (all randomized patients)	0.98 (0.82–1.17) [494 events]	0.62 (0.49–0.77) [309 events]
Cardiovascular death (patients with prior myocardial infarction) in pa	0.92 (0.69–1.23) [183 events]	0.59 (0.44–0.79) [183 events]
Trials in heart failure and a reduced ejection fraction (with or without diabetes)		
	DAPA-HF (dapagliflozin)	EMPEROR-Reduced (empagliflozin)
Cardiovascular death or hospitalization for heart failure	0.75 (0.65–0.85) [877 events]	0.75 (0.65–0.86) [823 events]
First hospitalization for heart failure	0.70 (0.59–0.83) [549 events]	0.69 (0.59–0.81) [588 events]
Renal composite endpoint	0.71 (0.44–1.16) [67 events]	0.50 (0.32–0.77) [88 events]
Cardiovascular death (all randomized patients)	0.82 (0.69–0.98) [500 events]	0.92 (0.75–1.12) [389 events]

Treatment effects are shown as hazard ratios and 95% confidence intervals for the comparison of the SGLT2 inhibitor and placebo, along with the number of events across the two treatment groups which contributed to the analysis. The definition of serious adverse renal events varied somewhat from the trial to trial, but typically included the need for chronic dialysis or renal transplantation or a sustained and profound decline in glomerular filtration rate. Two different analyses are provided for the analysis of cardiovascular death in the two trials in patients with type 2 diabetes; the analysis in patients with a prior myocardial infarction is provided to ensure comparability of the patient cohorts in the two trials.

SGLT2, sodium–glucose co-transporter-2.

mineralocorticoid receptor antagonists and neprilysin inhibitors. These favourable effects can be achieved by drugs that can be given once daily and do not require uptitration, and their use is not accompanied by hypotension, bradycardia, hyperkalaemia, or azotaemia, concerns that often accompany the use of currently recommended treatments for heart failure. This remarkable replication supports the role of dapagliflozin and empagliflozin as a new standard of care for patients with heart failure and a reduced ejection fraction.

Conflict of interest: The authors of this paper were members of the Executive Committee for the EMPEROR-Reduced trial with empagliflozin, which was sponsored by Boehringer Ingelheim and Eli Lilly and Company. M.P. has consulted for Abbott, Actavis, Akcea, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Johnson & Johnson, NovoNordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. J.B. has received research support from the National Institutes of Health, Patient-Centred Outcomes Research and the European Union, and he has served as a consultant for Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, LinaNova, Luitpold, Medtronic,

Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, V-Wave Limited, and Vifor. G.F. has consulted for Boehringer Ingelheim, Novartis, Vifor, Servier, Medtronic and received lecture fees from Merck. S.D.A. has recently received fees for steering committee activity, advisory board work, and/or speaking from AstraZeneca, Bayer, Boehringer, Brahms, Novartis, Respicardia, Servier, and Vifor, and he has received grants for the execution of investigator-initiated trials from Abbott Vascular and Vifor. F.Z. has recently received steering committee or advisory board fees from Amgen, AstraZeneca, Bayer, Boehringer, Boston Scientific, Cardior, CVRx, Janssen, Livanova, Merck, Mundipharma, Novartis, NovoNordisk, and Vifor Fresenius.

References

- Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019;**393**:31–39.
- Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H,

- Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;**380**:2295–2306.
3. Results of the eValuation of ERTugliflozin Efficacy and Safety CardioVascular Outcomes Trial (VERTIS-CV). Presented at the American Diabetes Association, June 16, 2020. https://plan.core-apps.com/tristar_ada20/event/20ebfeed4106d06a95df4f665fab997d (3 August 2020).
 4. Packer M. Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes. *Diabetes Care* 2018;**41**:11–13.
 5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2019;**380**:347–357.
 6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;**373**:2117–2128.
 7. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. *Circulation* 2019;**139**:2516–2527.
 8. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. *Circulation* 2019;**139**:1384–1395.
 9. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. *Circulation* 2019;**139**:2528–2536.
 10. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. *Eur Heart J* 2016;**37**:1526–1534.
 11. Butler J, Anker SD. The ethics of conducting clinical trials with sodium-glucose cotransporter-2 inhibitors in heart failure: is placebo assignment justified in patients with comorbid diabetes mellitus and heart failure? *Circulation* 2017;**136**:1459–1461.
 12. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bøhlhávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozd J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019;**381**:1995–2008.
 13. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Juanatey JRG, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls S, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, for the EMPEROR-Reduced Trial Committees and Investigators. Cardiac and renal outcomes with empagliflozin in heart failure with a reduced ejection fraction. *N Engl J Med* 2020;doi: 10.1056/NEJMoa2022190.
 14. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 2020;doi.org/10.1016/S0140-6736(20)31824-9.